420 with CNW — How Missouri Activists Overcame Setbacks to Put Cannabis Measure on Upcoming Ballot

Cannabis reform activists in Missouri have managed to get their legalization bill on the November ballot after being bogged down by setbacks and nearly forced to give up on their bill. According to unofficial tallies, the Legal Missouri campaign had not collected enough signatures to qualify for the upcoming ballot by late July, being 2,275 signatures short. With the ballot fast approaching, many feared the campaign’s hope of gathering enough signatures in time would be dashed.

But activists behind the campaign managed to pull a major comeback, collecting the remaining 2,275 signatures by Aug. 9, 2022, and qualifying the legalization initiative for the upcoming ballot.

Missouri officials announced in early August that the Legal Missouri campaign had collected the required number of signatures and that the organization’s cannabis legalization measure would appear on Missouri’s November ballot.

Speaking at a press conference, Secretary of State Jay Ashcroft urged Missouri residents to educate themselves on ballot initiatives, including Initiative 2022-59, which he called “particularly lengthy.”

Before the Legal Missouri campaign managed to cover the deficit of signatures, it asked Ashcroft’s office to do an internal review of the signatures it had submitted, even providing the office with a list of signatures it believed had been disqualified incorrectly. Even though state law required that the campaign take its grievances to the court, this surprise maneuver worked, a feat that shocked even veterans who have been in the initiative petition game for years.

Attorney Chuck Hartfield said he has never seen an instance where such corrections were made outside of the court process in his years of representing initiative petition campaigns.

In May, the campaign had submitted around 400,000 signatures for its cannabis legalization initiative, and state law required that they achieve a signature threshold in at least six of Missouri’s eight congressional districts. Early reporting indicated that the campaign was falling behind in two congressional districts, with the campaign stating at the time that it was checking the results from officials for errors and that it was confident the initiative would qualify.

In a press release in early August, Legal Missouri 2022 campaign manager John Payne said that volunteers collected 100,000 signatures on top of those obtained by paid signature collectors, showing that there is plenty of grassroots support among Missouri residents who would like to legalize cannabis in the state. He said that if the signatures had not been reviewed, Missourians wouldn’t have had the chance to vote on cannabis legalization on the upcoming ballot, potentially making Missouri the 20th state to legalize recreational cannabis.

The resilience displayed by the advocates to ensure that the ballot initiative qualifies for the November polls exemplifies how the entire marijuana industry and its actors, such as American Cannabis Partners, go to great lengths to make progress despite insurmountable odds.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point
Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment
Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits
The company looks to capitalize on the growing global anti-hypertensive drugs market, which is projected to hit $27.81 billion in value by 2025, and maintains that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its latest addition to a growing body of corporate communication pieces in its line-up. Titled “The Power of Science to Stop a Killer,” this recent broadcast highlights the company’s progress in finding a potential solution for hypertension treatment, while also pointing out why a solution is much needed at this point (https://cnw.fm/6E6Dy).

Lexaria’s flagship offering, its patented DehydraTECH(TM) technology, has proven to improve ways through which active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.

This overall effectiveness has seen the technology’s application in various segments, including but not limited to nicotine replacement, CBD, antivirals, epilepsy, human hormones, and PDE5 inhibitors. Lexaria’s venture into the hypertension sector acknowledges that over 114 million adults in the United States are at risk of damage caused by hypertension. In addition, the condition contributed to over 670,000 deaths within the country in 2020 alone (https://cnw.fm/bzEwy).

In this broadcast, Lexaria highlighted the progress it has made in its clinical studies and its success so far, ever since it began developing DehydraTECH in 2014. Furthermore, it expressed its confidence that its proposed solution will not only be safer but also a better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits.

Lexaria has made significant advancements in its clinical processes, amassing a growing body of evidence that strongly supports the use of its technology in hypertension therapeutics. This is not just a relief to millions of patients living with the condition but also a welcome addition for the company’s shareholders. In the communication, Lexaria noted that its valuation looks attractive with arguably significant upside. As a result, it looks to rub shoulders and gain attention from the likes of Pfizer Inc. (NYSE: PFE), Merc & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN), and Novartis AG (NYSE: NVS).

ReportLinker projects that the global anti-hypertensive drugs market will be valued at $27.81 billion by 2025, up from $24.17 billion in 2020, representing a compound annual growth rate (“CAGR”) of 0.8% (https://cnw.fm/714TS). For comparison, each year, the United States spends an average of $131 billion in hypertension costs, with figures expected to go up, particularly given the low awareness of anti-hypertensive drugs amongst the population.

Lexaria is optimistic that with its DehydraTECH technology, hypertension treatment will not only be more accessible but also more efficient and effective, ultimately allowing for a better quality of life for patients and a healthier, more productive population.

The company is currently focusing on human clinical studies to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment. In addition, it is inching closer to approval by the United States Food and Drug Administration (“FDA”), having received positive feedback from the institution on its DehydraTECH-CBD proposals earlier this month (https://cnw.fm/uLYzv).

Lexaria’s management still maintains late 2022/early 2023 for its Investigational New Drug (“IND”) application with the FDA and remains confident that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Recent Studies Show Advanced Cancer Sufferers Could Benefit from Using Marijuana

Over the past couple of years, a surge in cannabis research has revealed that the controversial plant has a variety of medical applications. Despite being classified as a Schedule I drug with no medical application, studies have found that cannabis can be effective at alleviating conditions such as chronic pain, depression and insomnia. Furthermore, the U.S. Food and Drug Administration has also approved a CBD-based drug called Epidiolex to treat seizures in pediatric epilepsy.

In recent months, research into the impact of cannabis on cancer treatment has found that the plant can have a positive impact on cancer patients. Cancer is one of the deadliest killers in the country, taking more than 500,000 lives per year and costing billions of dollars for treatment. Although there are treatments that can stop cancers from growing and significantly increase patients’ quality of life, no cure for cancer currently exists.

Researchers have been working on developing new treatments for the deadly disease, with cannabis being one of the objects of interest. Cancer is often associated with costly and addictive pain medications, reduced life quality, and mental and emotional anguish. And while most cancer treatments are geared at alleviating physical discomfort, there are barely any treatments designed to treat the mental and psychological anguish that comes from having a severe or terminal illness.

Upstate University Hospital researchers sought to understand how cannabis could benefit cancer treatment by studying how advanced cancer patients reacted to medical cannabis treatment. Study authors write that the goal of the research was to analyze the characteristics of advanced cancer patients who had received medical cannabis under a palliative care program and to point out any barriers that prevent patients with cancer from accessing medical marijuana.

Study participants had to be enrolled in New York’s medical cannabis registry. Researchers from the Upstate University Hospital in Syracuse reviewed patient data that was collected from June 2017 to June 2020, analyzing data from patients who had been diagnosed with cancer by a practitioner who is certified by the New York Medical Marijuana program and who had received treatment at Upstate Medical University.

The researchers found that medical cannabis use had a positive impact on advanced cancer patients, with 48.14% of the patients who received a dose of medical marijuana reporting reduced pain, 44.95% saying that they used fewer opioids as a result, and 85.11% noting that cannabis use alleviated at least one symptom. Only 3.72% of the patients who used cannabis reported feeling any adverse effects.

Researchers concluded that medical cannabis seems to play a role in alleviating symptoms of advanced cancer with minimal side effects and called for more research to determine optimal delivery methods and doses for patients. In this regard, industry players such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are leading the way by coming up with different innovations that optimize consumers’ experience while using marijuana products.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Marijuana Firms in Virginia Expand Facilities Despite Uncertainty Over Recreational Sales

Last year, legislators in Virginia approved a measure to legalize its commercial recreational cannabis market and launch it in 2024, which would make it the first of its kind in the South. At the time, Democrats were in control of the state’s government. However, once Republicans reclaimed the governor’s mansion and the House of Delegates in November, whether the state’s adult-use program would actually be launched at the stipulated time was thrown into disarray.

Despite this, marijuana multistate operators remain focused on expanding their medical cannabis facilities. For instance, representatives from Columbia Care and Jushi Holdings have revealed that their central focus is on launching six dispensaries each, as permitted under state law. Jushi Holdings, which is based in Florida, and Columbia Care, which is based in New York, have medical marijuana licenses in the state of Virginia. Both firms also plan to expand related infrastructure such as manufacturing facilities and grow rooms.

Trent Woloveck, Jushi’s chief commercial director, stated that the company was expanding its full complement of grow rooms. He also revealed the company had opened its third store last month in Alexandria. Jushi Holdings also has dispensaries operating in Sterling and Manassas and plans to launch its Fairfax store soon. Construction has also begun for the firm’s fifth store, which will be located in Arlington, with work to finalize its sixth site in Woodbridge also ongoing.

On the other hand, Columbia Care has four dispensaries located in Virginia: Short Pump, Richmond, Virginia Beach and Portsmouth. The company’s vice president of public policy, Ngiste Abebe, stated that the company was focused on launching more locations so that they could serve as many customers as possible.

The companies are focused on the state of Virginia because the legislature made significant changes to its medical cannabis program, which included streamlining applications, which would enable patients to purchase products as soon as they obtained a physician’s recommendation. This is expected to increase demand.

Prior to these changes, patients who received a doctor’s medical marijuana recommendation had to wait at least half a year to receive the paperwork required from the Board of Pharmacy in the state.

The state’s medical cannabis program also continues to grow, laying the foundation for a recreational marijuana market. Projections show that the medical cannabis market in Virginia will rake in about $25 million in sales in 2022. This figure is expected to increase to $95 million in less than four years.

While there is still uncertainty regarding whether recreational sales will be launched on schedule in Virginia, the existing law offers hope that change is coming and that the industry and its leading actors such as Prime Harvest Inc. will witness reforms taking place in different jurisdictions at an increasing rate in the years to come.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Experts Say Federal Court Ruling in Maine Could Pave Way for Interstate Cannabis Commerce

Last week, a federal appellate court ruled that the law prohibiting nonresidents in Maine from owning medical cannabis businesses in the state violated the United States’ constitution. Stakeholders in the industry have been monitoring the case keenly, with many arguing that the dormant commerce clause of the constitution applies to the cannabis industry, despite ongoing federal marijuana prohibition.

Legal experts believe that this ruling may have extensive implications for interstate marijuana commerce, with some noting that it could create potential complications for social equity programs. In the 2 to 1 ruling, the U.S. Court of Appeals for the First Circuit stated that while marijuana was illegal federally, Congress had acknowledged the existence of a medical cannabis market via the Rohrabacher–Farr amendment, which barred the Department of Justice from interfering with state-legal medical marijuana markets using its funds. The ruling added that in approving this legislation in 2014 and renewing it yearly since then, Congress had also acknowledged that the cannabis market could continue existing in some circumstances without federal criminal enforcement.

The state of Maine had in the past eliminated the residency requirement for its adult-use cannabis market. If the appellate court ruling is not appealed, interested parties will now have the chance to operate and own medical cannabis dispensaries in the state.

It should be noted that this ruling is limited in scope because it only directly affects states within its jurisdiction, which include Maine, Rhode Island, Puerto Rico, New Hampshire and Massachusetts. Despite this, the ruling has still caught the attention of many in the country, as more states move to enact legislations to lay the groundwork for interstate cannabis commerce.

For instance, Senate President Nicholas Scutari of New Jersey recently filed a measure that would permit the governor to enter into agreements with other legal states to export and import marijuana. This measure is similar to another interstate commerce initiative that was filed and signed into law in 2019 by Governor Kate Brown of Oregon.

It is important to note that these agreements can only be drawn up if the state attorney general (AG) verifies that the measure’s implementation won’t bring about considerable legal risk to the state, and the law can only take effect if the Department of Justice issues guidance authorizing such activity or if the federal law changes.

Meanwhile, a measure introduced by Sen. Anna Caballero of California, which would permit the governor to enter into interstate cannabis commerce agreements, was cleared for floor consideration by an assembly committee recently.

When cannabis interstate commerce finally becomes legal, multistate operators such as Flora Growth Corp. (NASDAQ: FLGC) will find an easier time optimizing their operations across the different markets in which they wish to have a presence.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — DOT Tables New Guidelines on CBD on the Certification of Commercial Drivers

The cannabidiol (CBD) revolution has been fantastic to behold. In just a few short years, the cannabis extract went from virtual anonymity to being one of the most searched-for items on the web. CBD is said to have a plethora of medical applications, including alleviating anxiety, chronic pain and insomnia, and it has been subject to significant consumer and scientific interest in recent years.

However, cannabidiol use is still frowned upon by plenty of employers, including the federal government. This is despite the fact that unlike delta-9 THC, the main psychoactive agent in cannabis, CBD does not intoxicate users. In the same vein, a federal agency recently declared that commercial drivers who consume CBD are doing so “at their own risk.” The agency made this declaration in a federal handbook meant to guide medical examiners who issue certifications from the U.S. Department of Transportation (DOT).

Issued by the Federal Motor Carrier Safety Administration (FMCSA), the handbook is meant to guide medical examiners who carry out physical examinations on interstate commercial drivers. The handbook acknowledges that while CBD products should have less than 0.3% THC per dry weight as outlined in federal regulations, physical exam certifications can still be impacted by consuming CBD products.

The agency notes that drivers whose employment requires them to undergo physical examinations and receive certification from the DOT “cannot be physically qualified” if they use cannabis even if their home state allows medical and recreational cannabis use.

So why are drivers who use cannabidiol products at risk even though they typically don’t contain enough THC to intoxicate them? Poor regulation.

Since the CBD sector’s inception, industry stakeholders, CBD businesses and even lawmakers have complained about the lack of regulation. Even though many have repeatedly urged the U.S. Food and Drug Administration to create a comprehensive regulatory framework for years, the FDA has dragged its feet, resulting in a barely regulated industry flush with dishonest players that aren’t always concerned with quality control.

Studies have found that mislabeling, contamination and medical fraud are common in the nascent CBD sector. Researchers found that plenty of cannabis products are not only contaminated with more THC than is legally allowed, but they also contain harmful substances such as bacteria, heavy metals and pesticides. The FMCSA handbook explained that there is little federal oversight to make sure that CBD products are actually true to their labeling and that their claims of having less than 0.3% THC are accurate.

This means that commercial drivers could potentially build up enough THC to fail physical examinations. The agency emphasized that contamination due to CBD use will not be a viable excuse. Even so, the FMCSA handbook urged examiners to evaluate each driver on a case-by-case basis.

The solution to these guidelines that aren’t in tandem with the law in states where marijuana is legal can only be resolved once reforms are instituted at the federal level. Only then will consumers who buy cannabis products from legitimate companies such as American Cannabis Partners finally relax in the knowledge that indulging in a legal product will not cause them trouble with their employers.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology
The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued
Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost
The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program

As a follow-up to recent coverage by Zacks Small-Cap Research, which valued the company at $15.00 (https://cnw.fm/obZ1e), global innovator Lexaria Bioscience (NASDAQ: LEXX) provided information to its stakeholders that would help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.

“Valuation of equities is a complex task with innumerable risks and rewards that include far-reaching macro events as well as company-specific developments. It is nearly impossible to foresee all risks and rewards, but underlying logic-based evaluation is one way to provide a realistic framework of expectations that investors can use in their analysis,” the August 11 press release reads (https://cnw.fm/DGYh2).

One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (“FDA”), there are five steps to the drug development process: Discovery and Development, Preclinical Research, Clinical Research, FDA Drug Review, and, finally, FDA Post-Market Drug Safety Monitoring. However, not more than about 250 of 5,000-10,000 compounds tested during the Discovery stage successfully transition to the third step. Against this backdrop, Lexaria stands out, having completed the first two steps with its DehydraTECH-CBD for hypertension treatment, with favorable results to boot.

The company’s first advanced human clinical study (“HCS”) for hypertension, conducted in 2018, for example, showed that DehydraTECH drug delivery technology delivered 317% more CBD to the blood at 30 minutes. Later HCS’s evidenced rapid and sustained drop in blood pressure (HYPER-H21-1), up to a 23% average reduction in overnight blood pressure and reduced arterial stiffness (HYPER-H21-2), and a 41% overall reduction in pulmonary artery systolic pressure (“PASP”) in male subjects (HYPER-H21-3). Lexaria is set to announce results from its fourth HCS – HYPER-H21-4 – in Q4 2022 (https://cnw.fm/caWiK).

If the HYPER-H21-4 study were registered with the FDA, Lexaria notes, it would possibly be a Phase 1B or 2A study. This information lends color to the company’s valuation going by a guide prepared by Bay Bridge Bio, which notes that a company’s valuation increases as its drug development progresses from Phase 1 through Phase 3. For example, at the start of a Phase I trial, a biotech company’s valuation would be $88 million, a figure that would then rise to $248 million at the start of Phase 2 study, finally eclipsing the $1 billion mark to settle at $1.119 billion when the Phase III trial begins. The figures increase further following an FDA approval of the drug candidate.

Considering the FDA’s recent confirmation that it agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, the company’s accelerated drug development program for hypertension therapeutics could wend way to a multi-billion-dollar valuation in due course. The pharmaceutical industry is rife with examples of such possibilities.

In March, for example, Pfizer Inc. (NYSE: PFE) completed the acquisition of clinical-stage company Arena Pharmaceuticals for a total consideration of $6.7 billion. At the time of the acquisition, Arena was expecting results for its Phase 3 trial undertaken to evaluate the safety and efficacy of the etrasimod drug candidate in patients with active ulcerative colitis (https://cnw.fm/LRYMc).

As a December 2021 report by accounting firm PwC notes, big pharma is set to spend anywhere between $5 billion and $15 billion and, in some cases, as much as $50 billion in 2022 to purchase promising biotech companies and their IP, as they seek to bring on board in new drugs that can become serious revenue generators (https://cnw.fm/3KBKG). Such acquisitions attest that biotech companies with little to no revenue can still be worth billions.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Mothers in Indonesia Fight for Their Children to Have Access to Medical Cannabis

Medical cannabis has been found to be a viable treatment for a wide variety of medical conditions in recent years. Studies have revealed that the plant can be effective against health issues such as chronic pain, anxiety, insomnia and depression. Furthermore, the US Food and Drug Administration has approved the use of a CBD-based drug called Epidiolex to treat seizures in pediatric epilepsy.

In Indonesia, a group of mothers is fighting to get their children access to cannabis, a plant they say could alleviate the pain caused by illnesses such as cerebral palsy. Pika Sasi Kirana was diagnosed with cerebral palsy when she was around five years old despite being a relatively healthy child for most of her young life.

Pika’s mother, Santi Warastuti, said the little girl started vomiting and fainting regularly, which prompted her parents to take her to a hospital and learn of her condition. Her health deteriorated significantly once the parents received a written diagnosis, with physicians struggling to halt the progression of the condition or find a way to give Pika a little comfort.

None of the different medications and doses that the doctors prescribed for Pika were effective, her mother said. By the time Pika required round-the-clock care and could barely do anything for herself, Warastuti was desperate for a medication that could at least make her daughter feel more comfortable.

Even though Indonesia is famous for its tough drug laws, Warastuti turned her attention to one of the most controversial drugs on the planet: medical marijuana. Warastuti, who used to work as a fashion designer, had first heard of medical cannabis when her European boss told her about the drug’s wide range of medical applications and that medical cannabis use was steadily gaining traction in Europe.

When she moved back to Yogyakarta, her hometown, Warastuti met Dwi Pratiwi, another mother interested in medical cannabis treatments for her child. Pratiwi had taken her son Musa to Australia for medical marijuana treatment and was a plaintiff in a Constitutional Court case to legalize cannabis in Indonesia. Although Musa has since died, Pratiwi said that she saw firsthand how medical cannabis helped to ease Musa’s muscular atrophy and made it easier for him to fall asleep.

The efforts of Pratiwi, Warastuti and another mother whose child has cerebral palsy to legalize cannabis have been unsuccessful so far, with the country’s Constitutional Court rejecting a motion to review Indonesia’s 2009 narcotics law. Even so, Warastuti was happy that the court ordered the government to research the medical uses of cannabis despite rejecting the mothers’ motion to legalize medical marijuana.

If only the plight of these Indonesian children could be considered and the needed reforms made, parents of children in need of medical cannabis could one day make use of advanced technologies, including the vertical gardening equipment manufactured by companies such as Advanced Container Technologies Inc. (OTC: ACTX) to cultivate their own high-quality medicinal marijuana to cut the costs of treating children.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Uncertainty Grows Over When Germany Will Legalize Marijuana

Germany has spent the past couple of months mulling over whether or not it should legalize cannabis, a move that would potentially turn the country into the world’s largest market for legal cannabis. With Germany’s left-liberal government pushing on with plans to legalize adult-use cannabis in the country, the coalition government has undertaken a series of public hearings with cannabis growers, economists and health experts to help inform the legalization process.

If Germany chooses to legalize recreational cannabis, the move could put pressure on its neighbors to follow its lead and create enough momentum to change the UN convention barring the cultivation and sale of cannabis. The coalition government recently declared that it was going to introduce “the controlled supply of recreational cannabis” to adults via licensed cannabis shops. However, turning these words into a nationwide cannabis industry is proving to be quite a challenge.

Legalizing cannabis would require input from nearly every federal government ministry, making the entire legislative process extremely complex and time consuming. Drug and addiction commissioner Burkhard Blienert says that efforts to legalize cannabis would have to involve policing, agriculture, tax issues and youth protection, to name a few. The ideal cannabis industry would be one that allows adults to purchase cannabis from licensed specialty shops while prioritizing public health and the protection of minors.

Given that cannabis is in extremely high demand, a legal market is expected to attract millions of consumers, in turn generating billions of dollars in taxes. Based on estimates that show most of the 4 million Germans who consume cannabis do so occasionally, Dusseldorf-based economist Justus Haucap expects cannabis to have a market value of around €4 billion ($3.97 billion) to €5 billion ($4.96 billion) or about 400 tons.

During an expert meeting held at the Health Ministry last year, Haucap estimated that the possible savings made by the police force and judiciary coupled with possible revenue from cannabis taxes and social security contributions could add up to almost $5 billion per year. He was one of nearly 200 local and international experts who met to discuss marijuana legalization. According to drug commissioner Blienert, the government is expected to draft a cannabis bill based on key points before deliberating it in parliament.

He says that once the federal government has crafted a comprehensive cannabis bill, it will be up to parliament to pass the bill and facilitate the creation of a nationwide adult-use cannabis industry. According to industry representative Heitepriem, players in a potential German cannabis industry wouldn’t be able to participate in international trade due to European regulations and UN conventions. This means Germany will have to source all its cannabis internally, a feat that will require significant investment and a lead time of one to two years to allow producers to ramp up production.

By the time the German marijuana market is launched, its players could lag far behind companies such as Prime Harvest Inc., which are already operational in North America and well positioned to expand should laws change at the federal and international levels.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Featured in Top News Guide

Advanced Container Technologies (OTC: ACTX) today announced that it was featured in Top News Guide’s “Stock in Focus”. The publication wrote, “Following a key announcement from the company yesterday, it might be a good move for investors to take a bit of an interest in Advanced Container Technologies…” According to the report, ACTX stock is above the 20-day and 50-day moving averages of $0.60 and $0.63, respectively. Top News also referenced a recent ACTX press release regarding GrowPods, hydroponic modular farms that can be located almost anywhere. “The addition of one or two GrowPods is going to allow farmers to move into profitable fruits or vegetables, which offer higher margins throughout the year,” the report reads.

“We are pleased that GrowPods are receiving national attention,” said Douglas Heldoorn, CEO of Advanced Container Technologies. “GrowPods offer a way for farmers to cultivate high-quality crops and create new revenue streams, year-round. With so many small family farmers struggling, GrowPods offer a way to quickly begin growing high-margin ultra-clean crops that can usually command significantly higher prices at retail.”

To view the full press release, visit https://cnw.fm/EXLGB

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.